


REMARKS

Currently claims 1-18 are pending. Applicants amend claims 1, 5-9, 11, 13- and 15 to correct typographic errors, and to reduce the filing fee by, *inter alia*, removing multiple dependency. Claims 12 and 16-18 are cancelled as being in a form inappropriate to US practice. Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,



John L. Lemanowicz  
Attorney for Applicant  
Registration No. 37,380

Date: 8/9/06  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-8247  
Facsimile: 919-483-7988